Clinical trial · Observational
A Prospective Clinical Study to Validate a Preoperative Risk Scoring Model for LNM in GC Patients
A Prospective Clinical Study to Validate a Preoperative Risk Scoring Model for Lymph Node Metastasis in Gastric Cancer Patients
NCT06339307CI-TRIAL-00095386completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
In our prior research, a risk scoring model for the occurrence of lymph node metastasis in patients who underwent radical gastrectomy for gastric cancer was established. To further validate this scoring model, a prospective study has been designed with the aim of prospectively assessing the model's clinical applicability.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Gastric Cancer | Malignant Gastric Neoplasm | CURATED_BROADER | 0.80 |
| Lymph Node Metastasis | — | UNRESOLVED | — |
| Predictive Cancer Model | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (2)
- label
- with LNM
- description
- Patients with gastric cancer who underwent curative gastrectomy and developed lymph node metastasis.
- label
- without LNM
- description
- Patients with gastric cancer who underwent curative gastrectomy and did not develop lymph node metastasis.
Primary outcomes (1)
- measure
- lymph node metastasis
- timeFrame
- 1 month after curative surgery
- description
- Collect postoperative pathological data from gastric cancer patients who have undergone curative gastrectomy to determine the occurrence of lymph node metastasis.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: 1. Primary gastric adenocarcinoma; 2. Curative surgery (with R0 resection, excluding palliative surgery and cases with distant metastasis). Exclusion Criteria: 1. Patients with autoimmune diseases, inflammation, or hematological disorders; 2. Patients with a history of or concurrent other cancers; 3. Presence of active infection and inflammation (based on WBC count, patients with count of 10×10\^9 or higher should be evaluated through medical record examination for the presence of infection); 4. Active bleeding (as determined by endoscopic ultrasound and HGB ≤ 90); 5. Post neoadjuvant radiotherapy or chemotherapy; 6. History of blood transfusion, corticosteroid use, or leukocyte-stimulating medications within the past month prior to blood draw; 7. Incomplete clinical and pathological data.
References
Publications (0)
Data not yet available
No reference posted for this study.